Juliana Salazar, Esther Garcia-Planella, Agnès Fernández-Clotet, Maria Esteve, Javier P Gisbert, David Busquets, Alfredo Lucendo, Lucía Márquez, Jordi Guardiola, María Dolores Martín-Arranz, Eva Iglesias, David Monfort, Albert Villoria, Fiorella Cañete, Olga Bell, Elena Ricart, Yamile Zabana, María Chaparro, Eugeni Domènech, Jordi Gordillo
AIMS: Methotrexate (MTX) is used to induce and maintain remission in patients with steroid-dependent Crohn's disease (CD). Despite its proven efficacy, its use is limited due to associated adverse events. Polymorphisms involving folate pathway genes might influence MTX efficacy and toxicity. We aimed to assess the impact of certain polymorphisms on the therapeutic outcomes of MTX in CD. METHODS: Patients with CD who exclusively followed MTX monotherapy and fulfilled inclusion criteria were identified from the GETECCU ENEIDA registry...
February 18, 2024: British Journal of Clinical Pharmacology